# Zepbound for Sleep Apnea: What SURMOUNT-OSA Actually Found

By Ruth Calder, Enforcement Editor (https://glpwatchdog.org/authors/ruth-calder) | Published: 2026-08-19 | Updated: 2026-10-30

Canonical page: https://glpwatchdog.org/research/zepbound-for-sleep-apnea

> On December 20, 2024 the FDA cleared Zepbound for obstructive sleep apnea, and no other drug of any kind holds that indication. The trials cut breathing interruptions by 25 to 29 an hour, and left the average participant still inside the moderate band.

## Key points

- Cleared December 20, 2024, and still the only drug of any kind licensed for sleep apnea.
- AHI fell 25.3 events/hour without PAP and 29.3 with, against 5.3 and 5.5 on placebo, over 52 weeks.
- Subtract from the published baselines and the mean participant still had moderate OSA at week 52.
- In trial 2, PAP was withdrawn before measurement, so nothing tested drug and machine together.

On **December 20, 2024** the FDA cleared Zepbound for obstructive sleep apnea. No other drug of any kind carries that indication.[6] The license is narrow. It covers adults who have obesity as well as OSA at the moderate-to-severe end, and it positions the drug beside a calorie deficit and more activity rather than in place of them. It works: in the two SURMOUNT-OSA trials, breathing interruptions fell by 25.3 and 29.3 an hour against 5.3 and 5.5 on placebo.[1] What almost no coverage mentions is where that leaves people. Subtract those changes from the trial's own starting points and the average participant still had moderate sleep apnea at week 52. This is a large improvement, and it is not a cure.

## What the trials did

[SURMOUNT-OSA](https://glpwatchdog.org/research/trials/surmount-osa) was run as two separate 52-week trials rather than one. Trial 1 enrolled people who were not using positive airway pressure. Trial 2 enrolled people who were. Each assigned participants to placebo or to tirzepatide, at whichever of the two upper strengths (10 mg or 15 mg) the person tolerated. Both measured one primary endpoint: the change in the apnea-hypopnea index, meaning the number of times an hour that breathing stops or goes shallow during sleep.[1]

Splitting the trial that way was the right call, because the two groups are asking different questions. One is asking what the drug does for untreated apnea. The other is asking what it adds for someone already on a machine. Our [sleep apnea condition page](https://glpwatchdog.org/conditions/sleep-apnea) covers the condition itself, including who is at risk and how it is diagnosed.

## The published numbers

*SURMOUNT-OSA, both trials, at 52 weeks. AHI is events per hour of sleep. Every figure is a group mean.*

|   | Trial 1 — not using PAP | Trial 2 — using PAP |
| --- | --- | --- |
| Mean AHI at baseline | 51.5 | 49.5 |
| Change on tirzepatide | −25.3 | −29.3 |
| Change on placebo | −5.3 | −5.5 |
| Treatment difference | −20.0 | −23.8 |

Tirzepatide also improved every prespecified secondary endpoint against placebo: body weight, hypoxic burden, high-sensitivity C-reactive protein, [systolic blood pressure](https://glpwatchdog.org/research/glp1-and-blood-pressure), and patient-reported sleep impairment and disturbance.[1] Whether gains such as the blood pressure and C-reactive protein changes came from the weight loss or from better breathing is the subject of [a post hoc analysis of these trials](https://glpwatchdog.org/research/is-it-just-the-weight-loss). Gastrointestinal effects were the most commonly reported adverse events, mostly mild to moderate. That is the same profile the drug carries at any dose, covered in our [constipation guide](https://glpwatchdog.org/research/glp1-constipation-what-works) and the [side-effect timeline](https://glpwatchdog.org/tools/glp1-side-effect-timeline).

## Where that actually leaves you

Promotional coverage skips this step. The trial reports *change* in AHI, not the number people finished on. Do the subtraction yourself. In trial 1, a mean baseline of 51.5 less a mean change of 25.3 leaves about 26 events an hour. In trial 2, 49.5 less 29.3 leaves about 20.

Sleep apnea is graded as mild at 5 to 14.9 events an hour, moderate at 15 to 29.9, and severe at 30 or more.[3] So the average participant in both trials moved from severe apnea to moderate apnea. That is a meaningful shift and worth having. It is not the same as no longer having the condition, and someone reading “first drug approved for sleep apnea” could easily believe otherwise.

> In trial 1, a mean baseline of 51.5 less a mean change of 25.3 leaves about 26 events an hour, which is still moderate sleep apnea.

> **This is not a reason to stop using your machine.** Untreated moderate-to-severe OSA carries cardiovascular risk, and the decision to reduce or stop PAP therapy is made on a repeat sleep study, not on a weight change or a prescription. If the drug is working well enough that the question is worth asking, the way to ask it is to book the follow-up study with the clinician managing your apnea.

Trial 2 has one more wrinkle. For its participants, PAP was withdrawn before the polysomnography and the questionnaires were administered.[2] The trial-2 figures therefore describe what tirzepatide did on its own for people who had been on a machine, not what the drug and the machine achieve together. Nothing in SURMOUNT-OSA measured the combination.

## Sleep, as opposed to the index

An apnea-hypopnea index is a count. It is not the same as feeling rested, and a treatment can move one without moving the other. A 2025 analysis of the patient-reported measures collected inside SURMOUNT-OSA looked at this, and found significant improvements against placebo at week 52 in sleep-related impairment, sleep disturbance, daytime functioning and health-related quality of life, across several validated instruments.[2]

That matters. The count could have improved while people felt no different, and that is the outcome most drug trials in this space are not designed to detect.

## What about the other GLP-1 drugs

Only tirzepatide has the indication. Liraglutide was tested for this a decade ago: SCALE Sleep Apnea randomized 359 adults with obesity and moderate or severe OSA who were unwilling or unable to use PAP, and over 32 weeks the AHI fell by 12.2 events an hour against 6.1 on placebo, with weight down 5.7% against 1.6%.[3] That is a real effect, and a fraction of what tirzepatide produced.

Semaglutide has no dedicated sleep apnea trial. If a seller markets a compounded semaglutide product for sleep apnea, that claim is not standing on a trial in this condition, and marketing an unapproved use is a pattern we track on the [FDA warning letters](https://glpwatchdog.org/fda-warning-letters) page.

> **On the pooled analyses, read the fine print.** Two 2025 reviews gathered the whole evidence base: a systematic review of 5 randomized trials in 1,024 patients, finding a mean AHI change of 14.45 events an hour,[4] and a meta-analysis of 6 studies in 1,067 participants estimating a 9.48-event treatment difference.[5] The second reports tirzepatide outperforming liraglutide by a wide margin, but that comparison is assembled across separate trials rather than measured head to head. It is a reasonable inference, but not the same class of evidence as the SURMOUNT-OSA result itself. The individual trials, including one on what a CPAP machine still does that the drug does not, are in our [sleep apnea reading list](https://glpwatchdog.org/research/lists/top-glp1-sleep-apnea-studies).

## The coverage question

The approval changed who can plausibly get this covered. Before December 2024, a Zepbound prescription was a weight-management prescription, and a great many plans exclude weight-management drugs outright. An OSA diagnosis is a different clinical route, and [some plans that refuse the first will consider the second](https://glpwatchdog.org/research/does-unitedhealthcare-cover-zepbound-and-wegovy). [Anthem’s Medi-Cal plan](https://glpwatchdog.org/insurance/anthem) is one example: it dropped Zepbound for weight loss in January 2026 but still considers prior authorization requests for sleep apnea. Medicaid draws the same line: [its federal weight-loss exclusion is written against a use, not a drug](https://glpwatchdog.org/research/does-medicaid-cover-zepbound). Because the indication belongs to the brand, our [Zepbound for sleep apnea board](https://glpwatchdog.org/best/tirzepatide-providers/zepbound-for-sleep-apnea) lists only sellers that price brand Zepbound, with compounded tirzepatide left off.

It is not automatic. Expect prior authorization, expect a documented sleep study, and expect the plan to have [its own criteria for what counts](https://glpwatchdog.org/research/does-kaiser-cover-zepbound-and-wegovy). Our [insurance section](https://glpwatchdog.org/insurance) tracks what individual plans publish, and the [prior authorization letter generator](https://glpwatchdog.org/tools/glp1-prior-auth-letter-generator) assembles what a submission generally needs. What we cannot tell you is what your specific plan will do, and any seller who says they know is guessing.

If you are going through a telehealth seller, check that it can write the brand product at all, and how. [The Virtual NP](https://glpwatchdog.org/reviews/the-virtual-np), a nurse-practitioner practice, prescribes brand Zepbound and offers prior-authorization help, with the drug paid to the pharmacy or through insurance. [Brightmeds](https://glpwatchdog.org/reviews/brightmeds) writes Zepbound vial prescriptions for a consult fee, and LillyDirect bills the drug separately.

Others sell brand Zepbound for cash beside their compounded plans: [HeliMeds](https://glpwatchdog.org/reviews/helimeds) one order at a time with no auto-billing, [RxION Health](https://glpwatchdog.org/reviews/rxion-health), [WellMedRx](https://glpwatchdog.org/reviews/wellmedr) and [Tryozi](https://glpwatchdog.org/reviews/tryozi) by the month, and [Layla](https://glpwatchdog.org/reviews/layla) on a monthly plan. [Vytora Health](https://glpwatchdog.org/reviews/vytora-health) lists both brand Zepbound and Mounjaro, and [myRocky](https://glpwatchdog.org/reviews/myrocky) lists Mounjaro but not Zepbound. The molecule is the same, but only the Zepbound label carries the sleep apnea indication, which is the one an OSA-based coverage request leans on.

For what the drug does on the scale rather than in the sleep lab, our [tirzepatide results timeline](https://glpwatchdog.org/research/tirzepatide-results-timeline) works through the SURMOUNT weight-loss trials, and the [price tracker](https://glpwatchdog.org/price-tracker) carries a dated figure for every seller we follow.

## Frequently asked questions

### Is Zepbound FDA-approved for sleep apnea?

Yes, since December 20, 2024, for adults whose OSA sits at the moderate-to-severe end and who also have obesity. The license positions it beside a calorie deficit and more activity. No other drug of any kind holds that indication.

### Can I stop using CPAP if I take Zepbound?

That is not a decision to make on your own, and the trial data do not support assuming it. In SURMOUNT-OSA the average participant improved from severe sleep apnea to moderate sleep apnea, which is still a diagnosis. Whether PAP therapy can be reduced or stopped is determined by a repeat sleep study with the clinician managing your apnea.

### How much does Zepbound reduce sleep apnea?

In the two SURMOUNT-OSA trials, breathing interruptions fell by 25.3 events an hour in people not using PAP and 29.3 in people who were, against 5.3 and 5.5 on placebo, over 52 weeks. Starting points averaged 51.5 and 49.5 events an hour, so the mean participant finished around 26 and 20 respectively.

### Does Wegovy or Ozempic treat sleep apnea?

Neither is approved for it and semaglutide has no dedicated sleep apnea trial. Liraglutide was studied in SCALE Sleep Apnea and reduced the apnea-hypopnea index by 12.2 events an hour against 6.1 on placebo over 32 weeks, but it does not carry the indication either.

### Will insurance cover Zepbound for sleep apnea?

Sometimes. An OSA diagnosis is a different clinical route than an obesity one, and some plans that exclude weight-management drugs outright will consider it. Expect prior authorization and a documented sleep study. Coverage rules are set plan by plan, so the only reliable answer comes from your own plan documents.

## References

1. Malhotra A, Grunstein RR, Fietze I, et al. Tirzepatide for the Treatment of Obstructive Sleep Apnea and Obesity. New England Journal of Medicine. 2024. PMID: 38912654. https://pubmed.ncbi.nlm.nih.gov/38912654/
2. Kanu C, Shinde S, Chakladar S, et al. Effect of tirzepatide treatment on patient-reported outcomes among SURMOUNT-OSA participants with obstructive sleep apnea and obesity. Sleep Medicine. 2025. PMID: 40774158. https://pubmed.ncbi.nlm.nih.gov/40774158/
3. Blackman A, Foster GD, Zammit G, et al. Effect of liraglutide 3.0 mg in individuals with obesity and moderate or severe obstructive sleep apnea: the SCALE Sleep Apnea randomized clinical trial. International Journal of Obesity. 2016. PMID: 27005405. https://pubmed.ncbi.nlm.nih.gov/27005405/
4. Bardóczi A, Matics ZZ, Turan C, et al. Efficacy of incretin-based therapies in obesity-related obstructive sleep apnea: a systematic review and meta-analysis of randomized controlled trials. Sleep Medicine Reviews. 2025. PMID: 40633481. https://pubmed.ncbi.nlm.nih.gov/40633481/
5. Li M, Lin H, Yang Q, et al. Glucagon-like peptide-1 receptor agonists for the treatment of obstructive sleep apnea: a meta-analysis. Sleep. 2025. PMID: 39626095. https://pubmed.ncbi.nlm.nih.gov/39626095/
6. U.S. Food and Drug Administration. FDA Approves First Medication for Obstructive Sleep Apnea — press announcement, December 20, 2024. FDA. 2024. https://www.fda.gov/news-events/press-announcements/fda-approves-first-medication-obstructive-sleep-apnea

---

Cite as: GLP Watchdog, Ruth Calder, "Zepbound for Sleep Apnea: What SURMOUNT-OSA Actually Found", published 2026-08-19, updated 2026-10-30. https://glpwatchdog.org/research/zepbound-for-sleep-apnea

Canonical HTML page: https://glpwatchdog.org/research/zepbound-for-sleep-apnea

Medical disclaimer: Nothing here is medical advice. We report on this subject; we do not treat anyone. Whether to begin a medication, supplement, or treatment, whether to adjust it, and whether to stop are questions for a clinician licensed to answer them, who knows your history.
